News

Stay connected – Follow our latest updates and meet our team!

May 20, 2025

Visit Mabqi at Booth #40 during the 13th Antibody Industrial Symposium (AIS)

May 15, 2025

Mabqi to Attend 2025 BIO International Convention in Boston

May 13, 2025

Mabqi to Attend Antibody Engineering & Therapeutics Europe 2025

April 30, 2025

Mabqi to Attend BioEquity Europe 2025

April 15, 2025

Mabqi welcomes Prof. Karim Fizazi as Medical Advisor

April 13, 2025

Mabqi is attending Meet2Win in Bordeaux, France

Mabqi shows first-in-class and best-in-class proprietary functional antibodies with high therapeutic potential in oncology

March 25, 2025

Mabqi is attending RESI Europe Conference 2025 in Barcelona, Spain

Mabqi secures a €5 million non-dilutive financing from the France 2030 public investment plan to advance preclinical development of it’s lead antibody candidate MQI-201 in oncology

February 26, 2025

Mabqi secures a €5 million funding for lead antibody candidate MQI-201 from France 2030

February 17, 2025

Join Mabqi at AACR Annual Meeting 2025 poster session in Chicago

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Mabqi is a biotechnology company focused on the discovery and development of fully human antibodies. Leveraging an innovative platform, we specialize in uncovering monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), pH-sensitive antibodies, and various other immunotherapy formats.

Legal notice